US5118667A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bone growth factors and inhibitors of bone resorption for promoting bone formation
Assignee: Celtrix Pharmaceuticals Inc
•
Filing: 1991-05-03
•
Granted: 1992-06-02
•
Expires: 2011-05-03
Abstract
Abstract Bone growth factors are used to stimulate new bone formation when administered with agents that inhibit bone resorption. These therapeutic combinations result in an enhanced rate of bone formation with an increase in bone mass.
Inventors
- 👤 Steven W. Adams
- 👤 Rosa Armstrong
- 👤 David Rosen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:57
CPC Classifications
A; A61; A61K; A61K45/00; A61K45/06; A61K31/00; A61K31/13; A61K31/135; A61K31/138; A61K31/56; A61K31/565; A61K31/66; A61K31/662; A61K31/663; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61K38/22; A61K38/23; A61P; A61P19/00; A61P19/08; A61P19/10; A61P3/00; A61P3/02; A61P35/00; A61P43/00
Claims Analysis
Total Claims: 72
Claim 1
Independent Claim
35 words
A method for stimulating new bone formation in a subject, comprising administering a pharmaceutically effective dose of a bone growth factor and a pharmaceutically effective dose of an inhibitor of bone resorption to the subject.
Claim 2
Independent Claim
35 words
A method for stimulating new bone formation in a subject, comprising administering a pharmaceutically effective dose of a bone growth factor and a pharmaceutically effective dose of an inhibitor of bone resorption to the subject.
Claim 3
Dependent Claim
12 words
The method of claim 1, wherein the bone growth facto is TGF-β.
Claim 4
Dependent Claim
13 words
The method of claim 1, wherein the bone growth factor is an activin.
Claim 5
Dependent Claim
16 words
The method of claim 1, wherein the bone growth factor is a bone morphogenic protein (BMP).
Claim 6
Dependent Claim
13 words
The method of claim 1, wherein the bone growth factor is an IGF.
Claim 7
Dependent Claim
14 words
The method of claim 1, wherein the bone growth factor is parathyroid hormone (PTH).
Claim 8
Dependent Claim
14 words
The method of claim 1, wherein the inhibitor of bone resorption is an estrogen.
Claim 9
Dependent Claim
14 words
The method of claim 1, wherein the inhibitor of bone resorption is a calcitonin.
Claim 10
Dependent Claim
14 words
The method of claim 1, wherein the inhibitor of bone resorption is a bisphosphonate.
Claim 11
Dependent Claim
14 words
The method of claim 1, wherein the inhibitor of bone resorption is sodium fluoride.
Claim 12
Dependent Claim
14 words
The method of claim 1, wherein the inhibitor of bone resorption is a tamoxifen.
Claim 13
Dependent Claim
10 words
The method of claim 1, wherein the subject is human.
Claim 14
Dependent Claim
19 words
The method of claim 1, wherein the bone growth factor and the inhibitor of bone resorption are administered sequentially.
Claim 15
Dependent Claim
19 words
The method of claim 1, wherein the bone growth factor and the inhibitor of bone resorption are administered simultaneously.
Claim 16
Independent Claim
34 words
A method for treating bone loss in a subject, comprising administering a pharmaceutically effective dose of a bone growth factor and a pharmaceutically effective dose of an inhibitor of bone resorption to the subject.
Claim 17
Independent Claim
34 words
A method for treating bone loss in a subject, comprising administering a pharmaceutically effective dose of a bone growth factor and a pharmaceutically effective dose of an inhibitor of bone resorption to the subject.
Claim 18
Dependent Claim
12 words
The method of claim 15, wherein the bone growth factor is TGF-β.
Claim 19
Dependent Claim
13 words
The method of claim 15, wherein the bone growth factor is an activin.
Claim 20
Dependent Claim
16 words
The method of claim 15, wherein the bone growth factor is a bone morphogenic protein (BMP).
Claim 21
Dependent Claim
13 words
The method of claim 15, wherein the bone growth factor is an IGF.
Claim 22
Dependent Claim
14 words
The method of claim 15, wherein the bone growth factor is parathyroid hormone (PTH).
Claim 23
Dependent Claim
14 words
The method of claim 15, wherein the inhibitor of bone resorption is an estrogen.
Claim 24
Dependent Claim
14 words
The method of claim 15, wherein the inhibitor of bone resorption is a calcitonin.
Claim 25
Dependent Claim
14 words
The method of claim 15, wherein the inhibitor of bone resorption is a bisphosphonate.
Claim 26
Dependent Claim
14 words
The method of claim 15, wherein the inhibitor of bone resorption is sodium fluoride.
Claim 27
Dependent Claim
14 words
The method of claim 15, wherein the inhibitor of bone resorption is a tamoxifen.
Claim 28
Dependent Claim
10 words
The method of claim 15, wherein the subject is human.
Claim 29
Dependent Claim
11 words
The method of claim 15, wherein the bone loss is osteoporosis-related.
Claim 30
Dependent Claim
11 words
The method of claim 15, wherein the bone loss is osteomalacia-related.
Claim 31
Dependent Claim
11 words
The method of claim 15, wherein the bone loss is osteohalisteresis-related.
Claim 32
Dependent Claim
11 words
The method of claim 15, wherein the bone loss is age-related.
Claim 33
Dependent Claim
14 words
The method of claim 15, wherein the bone loss is related to steroid therapy.
Claim 34
Dependent Claim
11 words
The method of claim 15, wherein the bone loss is osteoarthritis-related.
Claim 35
Dependent Claim
14 words
The method of claim 15, wherein the bone loss is related to Paget's disease.
Claim 36
Dependent Claim
13 words
The method of claim 15, wherein the bone loss is related to cancer.
Claim 37
Dependent Claim
11 words
The method of claim 34, wherein the cancer is multiple myeloma.
Claim 38
Dependent Claim
10 words
The method of claim 15, wherein the treatment is prophylactic.
Claim 39
Dependent Claim
19 words
The method of claim 15, wherein the bone growth factor and the inhibitor of bone resorption are administered sequentially.
Claim 40
Dependent Claim
19 words
The method of claim 15, wherein the bone growth factor and the inhibitor of bone resorption are administered simultaneously.
Claim 41
Dependent Claim
35 words
A composition for inducing bone formation in a subject, comprising a pharmaceutically effective dose of a bone growth factor and a pharmaceutically effective dose of an inhibitor of bone loss in a pharmaceutically acceptable excipient.
Claim 42
Dependent Claim
35 words
A composition for inducing bone formation in a subject, comprising a pharmaceutically effective dose of a bone growth factor and a pharmaceutically effective dose of an inhibitor of bone loss in a pharmaceutically acceptable excipient.
Claim 43
Dependent Claim
12 words
The composition of claim 39, wherein the bone growth factor is TGF-β.
Claim 44
Dependent Claim
13 words
The composition of claim 39, wherein the bone growth factor is an activin.
Claim 45
Dependent Claim
16 words
The composition of claim 39, wherein the bone growth factor is a bone morphogenic protein (BMP).
Claim 46
Dependent Claim
13 words
The composition of claim 39, wherein the bone growth factor is an IGF.
Claim 47
Dependent Claim
14 words
The composition of claim 39, wherein the bone growth factor is parathyroid hormone (PTH).
Claim 48
Dependent Claim
14 words
The composition of claim 39, wherein the inhibitor of bone resorption is an estrogen.
Claim 49
Dependent Claim
14 words
The composition of claim 39, wherein the inhibitor of bone resorption is a calcitonin.
Claim 50
Dependent Claim
14 words
The composition of claim 39, wherein the inhibitor of bone resorption is a bisphosphonate.
Claim 51
Dependent Claim
14 words
The composition of claim 39, wherein the inhibitor of bone resorption is sodium fluoride.
Claim 52
Dependent Claim
14 words
The composition of claim 39, wherein the inhibitor of bone resorption is a tamoxifen.
Claim 53
Dependent Claim
22 words
The composition of claim 39, wherein the molar ratio of bone growth protein to inhibitor of bone resorption is 10:1 to 1:10.
Claim 54
Dependent Claim
22 words
The composition of claim 39, wherein the molar ratio of bone growth protein to inhibitor of bone resorption is 5:1 to 1:1.
Claim 55
Dependent Claim
18 words
The composition of claim 39, wherein the bone growth protein is conjugated to the inhibitor of bone resorption.
Claim 56
Dependent Claim
10 words
The composition of claim 39, further comprising a sustained-release vehicle.
Claim 57
Dependent Claim
35 words
A composition for treating bone loss in a subject, comprising a pharmaceutically effective dose of a bone growth factor and a pharmaceutically effective dose of an inhibitor of bone resorption in a pharmaceutically acceptable excipient.
Claim 58
Dependent Claim
35 words
A composition for treating bone loss in a subject, comprising a pharmaceutically effective dose of a bone growth factor and a pharmaceutically effective dose of an inhibitor of bone resorption in a pharmaceutically acceptable excipient.
Claim 59
Dependent Claim
12 words
The composition of claim 54, wherein the bone growth factor is TGF-β.
Claim 60
Dependent Claim
13 words
The composition of claim 54, wherein the bone growth factor is an activin.
Claim 61
Dependent Claim
16 words
The composition of claim 54, wherein the bone growth factor is a bone morphogenic protein (BMP).
Claim 62
Dependent Claim
13 words
The composition of claim 54, wherein the bone growth factor is an IGF.
Claim 63
Dependent Claim
14 words
The composition of claim 54, wherein the bone growth factor is parathyroid hormone (PTH).
Claim 64
Dependent Claim
14 words
The composition of claim 54, wherein the inhibitor of bone resorption is an estrogen.
Claim 65
Dependent Claim
14 words
The composition of claim 54, wherein the inhibitor of bone resorption is a calcitonin.
Claim 66
Dependent Claim
14 words
The composition of claim 54, wherein the inhibitor of bone resorption is a bisphosphonate.
Claim 67
Dependent Claim
14 words
The composition of claim 54, wherein the inhibitor of bone resorption is sodium fluoride.
Claim 68
Dependent Claim
14 words
The composition of claim 54, wherein the inhibitor of bone resorption is a tamoxifen.
Claim 69
Dependent Claim
22 words
The composition of claim 54, wherein the molar ratio of bone growth factor to inhibitor of bone resorption is 10:1 to 1:10.
Claim 70
Dependent Claim
22 words
The composition of claim 54, wherein the molar ratio of bone growth factor to inhibitor of bone resorption is 5:1 to 1:1.
Claim 71
Dependent Claim
18 words
The composition of claim 54, wherein the bone growth factor is conjugated to the inhibitor of bone resorption.
Claim 72
Dependent Claim
10 words
The composition of claim 54, further comprising a sustained-release vehicle.
References Cited (Backward Citations)
US4294753A
Cited
US4455256A
Cited
US4434094A
Cited
US4608199A
Cited
EP0212474A2
Cited
WO1988000205A1
Cited
WO1989009788A2
Cited
WO1989009787A2
Cited
EP0436469A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-06-02 | 1995-12-02 | 1996-06-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-06-02 | 1999-12-02 | 2000-06-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-06-02 | 2003-12-02 | 2004-06-02 | $7700.00 | Window Closed / Lapsed |